Pharvaris to Present at SVB Securities Global Biopharma Conference
ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will present at the SVB Securities Global Biopharma Conference taking place virtually from February 14–16, 2023.
Related news for (PHVS)
- Pharvaris to Present at the WSAAI Annual Meeting 2024
- Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
- Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
- Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
- Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop